Edwards Lifesciences
About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Employees: 19,800
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
16% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 102
1% more funds holding
Funds holding: 1,254 [Q1] → 1,270 (+16) [Q2]
0.99% more ownership
Funds ownership: 80.65% [Q1] → 81.65% (+0.99%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 14 [Q1] → 14 (+0) [Q2]
2% less capital invested
Capital invested by funds: $46.3B [Q1] → $45.4B (-$846M) [Q2]
3% less repeat investments, than reductions
Existing positions increased: 449 | Existing positions reduced: 463
7% less call options, than puts
Call options by funds: $276M | Put options by funds: $297M
Research analyst outlook
26 Wall Street Analysts provided 1 year price targets over the past 3 months
26 analyst ratings
Morgan Stanley Patrick Wood 67% 1-year accuracy 8 / 12 met price target | 2%upside $70 | Equal-Weight Reinstated | 11 Oct 2024 |
RBC Capital Shagun Singh 68% 1-year accuracy 40 / 59 met price target | 10%upside $75 | Outperform Maintained | 8 Oct 2024 |
Canaccord Genuity William Plovanic 52% 1-year accuracy 11 / 21 met price target | 4%downside $66 | Hold Maintained | 7 Oct 2024 |
Evercore ISI Group Vijay Kumar 76% 1-year accuracy 29 / 38 met price target | 2%upside $70 | In-Line Maintained | 1 Oct 2024 |
Citigroup Joanne Wuensch 72% 1-year accuracy 23 / 32 met price target | 12%upside $77 | Buy Maintained | 1 Oct 2024 |
Financial journalist opinion
Based on 76 articles about EW published over the past 30 days